
Teleflex (TFX) Stock Forecast & Price Target
Teleflex (TFX) Analyst Ratings
Bulls say
Teleflex's financial outlook is supported by a projected sales growth rate of approximately 6% off a nearly $1 billion base in its interventional business, indicating a strong market position. Additionally, the company's strategic focus on cost reduction and the introduction of new product lines are expected to enhance operating margins while facilitating double-digit earnings growth. With a bull case scenario projecting organic revenue growth between 4-6% and the potential for further acquisitions, Teleflex stands to benefit from favorable shifts towards higher growth and higher margin products in the coming years.
Bears say
Teleflex's recent performance has raised significant concerns, particularly following its fourth-quarter 2024 results, which revealed a substantial drop in share value and a disappointing revenue guidance for 2025 that fell well below market expectations. The company's forecasted revenue growth of only 1.0-2.0% year-over-year contrasts sharply with the Street's projection of 4.5%, indicating potential challenges in key segments, notably the UroLift product line and overall price pressures in office settings. Additionally, the planned acquisition of Biotronik's Vascular Intervention business for approximately $820 million, coupled with the division of the company into two parts, raises further apprehension regarding the strategic direction and financial implications for Teleflex going forward.
This aggregate rating is based on analysts' research of Teleflex and is not a guaranteed prediction by Public.com or investment advice.
Teleflex (TFX) Analyst Forecast & Price Prediction
Start investing in Teleflex (TFX)
Order type
Buy in
Order amount
Est. shares
0 shares